



Variable responsiveness to GLP-1 therapies

UK ABCD Audit n=12,955 T2DM starts on exenatide 5-10ug BD (6,717) and liraglutide 0.6-1.2mg OD (6,238) for 20-32 wks. Scatter plots of Δ HbA_{1c} vs Δ body weight. Baseline HbA_{1c} 9.4%, BMI 39 kg/m², weight 110kg. 28% exenatide and 39% liraglutide already on insulin - - - lines indicate \downarrow HbA_{1c} \geq 1% or \downarrow body wt \geq 3% as required by NICE to continue therapy



N=1882. 60.1% of patients achieved both HbA_{1c} and wt reduction, but only 28.6% achieved this to the criteria levels set by NICE.



N=1023. 59.3% of patients achieved both HbA_{1c} and wt reduction, but only 25.0% achieved this to the criteria levels set by NICE.